Compare Peptides
Select any two compounds for a side-by-side comparison of mechanism, uses, risks, and FDA regulatory status.
Popular comparisons
A once-weekly GLP-1 receptor agonist FDA-approved for type 2 diabetes and cardiovascular risk reduction. Developed by Eli Lilly as a predecessor to tirzepatide. One of the most prescribed GLP-1 agonists globally.
The first GLP-1 receptor agonist approved by the FDA, originally derived from Gila monster saliva. Available in twice-daily (Byetta) and once-weekly (Bydureon) formulations. Paved the way for semaglutide and tirzepatide.
A GLP-1 analog fused to a modified IgG4 Fc fragment, extending its half-life to approximately 5 days. Activates GLP-1 receptors to stimulate insulin secretion, suppress glucagon, slow gastric emptying, and reduce appetite.
Synthetic version of exendin-4, a peptide found in Gila monster venom that shares 53% homology with human GLP-1 but resists DPP-4 degradation. Stimulates insulin secretion, suppresses glucagon, slows gastric emptying, and promotes satiety.
- Type 2 diabetes
- Cardiovascular risk reduction
- Moderate weight loss
- Blood sugar regulation
- Type 2 diabetes
- Blood sugar regulation
- Modest weight loss
- GI side effects (nausea, diarrhea, vomiting)
- Pancreatitis (rare)
- Thyroid C-cell tumors (animal studies)
- Injection site reactions
- Hypoglycemia when combined with insulin
- Nausea (common, especially initially)
- Pancreatitis (rare)
- Injection site nodules (Bydureon)
- Renal impairment
- Thyroid C-cell tumors (animal studies)
FDA-approved as Trulicity (2014) for type 2 diabetes and cardiovascular risk reduction (REWIND trial). Once-weekly injection via single-dose pen. One of the top-selling GLP-1 drugs globally.
FDA-approved as Byetta (2005, twice daily) and Bydureon (2012, once weekly). The first-in-class GLP-1 agonist. Largely superseded by semaglutide for new prescriptions but still widely used.
This comparison is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy.